Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Evive Biotech
Nine prominent drug candidates are awaiting an FDA approval decision in the next few months. With the help of Biomedtracker's Early 2022 Outlook Report, we take a look at the potential launches likely to shake up the market from HIV to wet AMD.
BeiGene’s $3.5bn Shanghai IPO and CANbridge’s Hong Kong listing, as well as Dizal’s offering on the STAR market and five financing rounds totaling $508.5m help set a record for Chinese biotech fundraising in the last month of 2021.
Marketing applications for 10 new drugs have been added to the latest list of products under review by the European Medicines Agency.
- Other Names / Subsidiaries
- Generon (Shanghai) Corporation Ltd
- Generon BioMed Holding Ltd.